Understand · Treat · Recover

Maintenance Therapy After Initial Treatment

Maintenance aims to prolong control after a response; it is not necessary or appropriate for every patient.

This guide is educational and does not replace individual medical assessment. Do not start, stop or change treatment without the treating team. Cancer Aware supports patients and families worldwide. Drug approvals, availability, affordability and care pathways vary by country.

Chapter 11 of 20

The decision after chemotherapy

The team considers stage, subtype, response to platinum, BRCA and HRD results, prior bevacizumab, side effects and patient priorities. Maintenance options can include a PARP inhibitor, bevacizumab or a selected combination. Observation is also an active plan in appropriate circumstances. A treatment that benefits one molecular subgroup may offer a different balance in another.

Understanding the options

PARP inhibitors interfere with DNA repair and are particularly relevant in selected BRCA-mutated or HRD-positive settings. Bevacizumab targets blood-vessel growth. Combining olaparib with bevacizumab has a defined role in eligible HRD-positive advanced disease following appropriate initial treatment. The exact drug, indication and eligibility must match the current local label. First-line maintenance and recurrent-disease maintenance are separate decisions.

Monitoring and trade-offs

  • PARP inhibitors can cause fatigue, nausea and low blood counts; rare serious marrow disorders require prompt investigation of persistent abnormalities.
  • Bevacizumab requires blood-pressure and urine-protein monitoring and careful assessment of bleeding, bowel and wound-healing risks.
  • Discuss the absolute expected benefit, visit burden, affordability and effect on daily life.

How long does it continue?

Duration depends on the agent, setting, response and tolerance; some first-line plans have a defined end while others are continued according to the treatment protocol. Do not assume indefinite therapy. Some later-line PARP indications have been restricted or withdrawn in certain countries. Ask about the current indication rather than relying on an older article or another person’s prescription.

Key takeaway

Choose maintenance by setting, biomarkers and personal benefit–risk balance.

Common questions

Does maintenance mean the chemotherapy failed?

No. It is often considered because chemotherapy achieved a response.

Must every patient receive it?

No. Eligibility and the balance of benefit and harm differ.

Is HRD the same as BRCA?

No. BRCA is one part of a broader DNA-repair picture.

Can treatment be paused for low counts?

Yes, under the treating team’s direction and monitoring.

Is a drug approved worldwide if the FDA approves it?

No. National approvals, reimbursement and availability differ.

Sources and further reading